Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)
Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Various cytotoxic agents have been evaluated in advanced hepatocellular carcinoma, but
response rates have been low with significant toxicity, most often due to parenchymal liver
disease. The three agents etoposide, oxaliplatin and capecitabine each has sparse efficacy as
single agents, but the combination may act synergistically with an acceptable toxicity
profile.
Phase:
Phase 2
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborator:
Morten Ladekarl, MD, DMSc., Dept. of Oncology, Århus Sygehus, Århus